Lululemon appears undervalued on traditional metrics, but weak revenue growth and rising costs undermine its risk-reward ...

Research on statistical arbitrage in U.S. equities (1997–2007) shows that PCA-based strategies achieved average annual Sharpe ...

Discover why Novo Nordisk is a top buy with strong GLP-1 drug growth, robust fundamentals, and defensive value.